Article
The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
The Journal of clinical psychiatry - 1 Jan 2005
de Leon Jose, Susce Margaret T, Pan Run-Mei, Fairchild Maureen, Koch Walter H, Wedlund Peter J
Abstract excerpt
OBJECTIVE: The cytochrome P450 2D6 (CYP2D6) enzyme metabolizes risperidone. CYP2D6 poor metabolizers have no CYP2D6 activity (7% of whites and 1%-2% of other races). This study tested whether the CYP2D6 poor metabolizer phenotype was associated with adverse drug reactions (ADRs) and discontinuation due to ADRs. METHOD: Adult inpatients and outpatients were recruited from July 2000 to March 2003 including (1) 325...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.